ClinicalTrials.gg
RecruitingNCT06121843Updated Jul 16, 2026

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 interventional study of BMS-986393 and Alnuctamab in Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Recruiting at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
187
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.

Planned enrollment
34th of 108
187 · median 83
Started
2024
with 6 others
Phase 1
40 of 149
2 open now
Primary completion
2028-08
later than 12 of 17 live
Registered
137th of 149
by date

Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 34th largest by planned enrollment of the 108 interventional ones that give a count, is one of 7 that started in 2024, is one of 40 in phase 1, reaches primary completion later than 12 of the 17 other live ones, and was the 137th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Multiple Myeloma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • BMS-986393
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • First-in-human
  • Alnuctamab
  • Mezigdomide
  • Iberdomide
  • CC-95266
  • GPRC5D
  • GPRC5D CAR T
  • Cell Therapy
  • CAR T cell therapy
  • Combination therapy
  • elranatamab
  • arlocabtagene autoleucel
  • arlo-cel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of multiple myeloma (RRMM) treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent (Part 2, Arm E).
  • Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
  • performance status of 0-1.
  • Adherence to requirements.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
  • Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2).
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
187 participants (estimated)

Study arms

  • Experimental
    Arm A: BMS-986393 + Alnuctamab

    Drug: BMS-986393 · Drug: Alnuctamab

  • Experimental
    Arm B: BMS-986393 + Mezigdomide

    Drug: BMS-986393 · Drug: Mezigdomide

  • Experimental
    Arm C: BMS-986393 + Iberdomide

    Drug: BMS-986393 · Drug: Iberdomide

  • Experimental
    Arm D: BMS-986393 + Elranatamab

    Drug: BMS-986393 · Drug: Elranatamab

  • Experimental
    Arm E: BMS-986393 + Mezigdomide and Dexamethasone

    Drug: BMS-986393 · Drug: Mezigdomide · Drug: Dexamethasone

Interventions

  • DrugArlocabtagene autoleucelStudies of Arlocabtagene autoleucelArlocabtagene autoleucel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Specified dose on specified days

    Also known as: CC-95266, Arlocabtagene autoleucel, arlo-cel

  • Specified dose on specified days

    Also known as: BMS-986349, CC-93269, EM901

  • Specified dose on specified days

    Also known as: BMS-986348, CC-92480

  • Specified dose on specified days

    Also known as: BMS-986382, CC-220

  • Specified dose on specified days

    Also known as: Elrexfio

  • Specified dose on specified days

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to 2 years

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to 2 years

  3. Incidence of adverse events of special interest (AESI)

    Time frame: Up to 2 years

  4. Incidence of AEs leading to discontinuation

    Time frame: Up to 2 years

  5. Number of Deaths

    Time frame: Up to 2 years

  6. Establish recommended Phase 2 dose (RP2D)

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall response rate (ORR)

    Time frame: Up to 2 years

  2. Complete response rate (CRR)

    Time frame: Up to 2 years

  3. Very good partial response rate (VGPRR)

    Time frame: Up to 2 years

  4. Maximum observed concentration (Cmax) of arlocabtagene autoleucel

    Time frame: Up to 2 years

  5. Time of maximum observed concentration (tmax) of arlocabtagene autoleucel

    Time frame: Up to 2 years

  6. Area under the concentration-time curve from time 0 to 28 days [AUC (0-28D)] of arlocabtagene autoleucel

    Time frame: Up to 2 years

07

Study locations

17 of 19 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
    Recruiting
    • Susan Bal, Site 0008 · Contact205-934-1908
  • Mayo Clinic in Arizona - Phoenix
    Phoenix, Arizona 85054, United States
    Recruiting
    • Julia Wiedmeier-Nutor, Site 0002 · Contact855-776-0015
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Recruiting
    • Myo Htut, Site 0028 · Contact626-256-4673
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
    Recruiting
    • Sikander Ailawadhi, Site 0005 · Contact904-953-0853
  • Northside Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
    • Scott Solomon, Site 0006 · Contact404-255-1930
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
    • Jacalyn Rosenblatt, Site 0027 · Contact617-667-9920
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Omar Nadeem, Site 0011 · Contact617-632-3000
  • Mayo Clinic in Rochester, Minnesota
    Rochester, Minnesota 55905, United States
    Recruiting
    • Taxiarchis Kourelis, Site 0001 · Contact855-776-0015
  • University Of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Recruiting
    • Christopher D'Angelo, Site 0010 · Contact402-559-8110
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601-2191, United States
    Recruiting
    • David Siegel, Site 0004 · Contact551-996-8704
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
    Recruiting
    • Ehsan Malek, Site 0007 · Contact216-286-4441
  • Laura and Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
    Recruiting
    • Jingmei Hsu, Site 0022 · Contact646-501-4848
  • Local Institution - 0009
    New York, New York 10032, United States
    Completed

    Not enrolling at this site.

  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Sham Mailankody, Site 0012 · Contact646-608-3712
  • Local Institution - 0023
    Pittsburgh, Pennsylvania 15232, United States
    Withdrawn

    Not enrolling at this site.

  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
    • Jesus Berdeja, Site 0025 · Contact615-329-0570
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Krina Patel, Site 0003 · Contact713-792-6662
  • Arthur J.E. Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
    • Nizar Bahlis, Site 0013 · Contact4032202801
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Christine Chen, Site 0024 · Contact4169464501
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2028, 53 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 53 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2023
First posted
Nov 8, 2023
StartActual
Feb 22, 2024
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06121843
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Feb 22, 2024
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion